Knowledge about coronavirus disease 2019 (COVID-19) is rapidly evolving. Although patients with inflammatory bowel disease do not appear to be at increased risk for COVID-19, the potential impact of immunosuppressive therapies on patients with inflammatory bowel disease infected with severe acute respiratory syndrome coronavirus 2 is a concern for clinicians and patients.